Source: Health Products Regulatory Authority (IE) Revision Year: 2022 Publisher: Menarini International Operations Luxembourg S.A., 1, Avenue de la Gare, 1611 Luxembourg, Luxembourg
Omesar 10 mg film-coated tablets.
| Pharmaceutical Form |
|---|
|
Film-coated tablets. White, circular, film-coated tablets with C13 debossed on one side. |
Olmesartan medoxomil.
Each film-coated tablet contains 10 mg olmesartan medoxomil.
Excipient with known effect: Each film-coated tablet contains 61.6 mg lactose monohydrate.
For the full list of excipients, see section 6.1
| Active Ingredient | Description | |
|---|---|---|
| Olmesartan medoxomil |
Olmesartan medoxomil is a potent, orally active, selective angiotensin II receptor (type AT1) antagonist. It is expected to block all actions of angiotensin II mediated by the AT1 receptor, regardless of the source or route of synthesis of angiotensin II. The selective antagonism of the angiotensin II (AT1) receptors results in increases in plasma renin levels and angiotensin I and II concentrations, and some decrease in plasma aldosterone concentrations. |
| List of Excipients |
|---|
|
Tablet core: Cellulose, microcrystalline Tablet coat: Titanium dioxide (E171) |
Laminated polyamide / aluminium/polyvinyl chloride // aluminium blister pack.
Packs of 14, 28, 30, 56, 84, 90, 98 and 10 × 28 film-coated tablets.
Packs with perforated unit dose blisters of 10, 50 and 500 film-coated tablets.
Not all pack sizes may be marketed.
Menarini International Operations Luxembourg S.A., 1, Avenue de la Gare, 1611 Luxembourg, Luxembourg
PA0865/011/001
Date of first authorisation: 19th September 2003
Date of last renewal: 25th April 2008
| Drug | Countries | |
|---|---|---|
| OMESAR | Ireland, Malta, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
